Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $8.97 and last traded at $9.01, with a volume of 512437 shares trading hands. The stock had previously closed at $9.46.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Bank of America raised their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Guggenheim upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.88.
Read Our Latest Analysis on Amicus Therapeutics
Amicus Therapeutics Trading Down 4.7 %
The firm has a fifty day moving average of $9.95 and a 200-day moving average of $10.55. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -26.53 and a beta of 0.62.
Insider Buying and Selling at Amicus Therapeutics
In related news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at $10,161,054.84. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 22,901 shares of company stock valued at $259,863 over the last 90 days. 2.20% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Amicus Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Millennium Management LLC boosted its holdings in Amicus Therapeutics by 1,758.9% in the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after purchasing an additional 1,792,277 shares during the period. William Blair Investment Management LLC increased its stake in Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock valued at $128,993,000 after purchasing an additional 1,477,084 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Amicus Therapeutics during the third quarter worth $13,530,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock worth $21,765,000 after buying an additional 1,192,489 shares during the last quarter.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
